Phaseline

Companies › Metro International Biotech

Metro International Biotech: clinical trials, targets and expected readouts

2 active drug programs in 3 registered trials: 3 Phase 1; Other; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
MIB-725
Modified precursor of the NAD+ biosynthetic pathway
–Phase 1Healthy AdultsDec 2026
Nicotinamide Mononucleotide (NMN)
NAD+ precursor; substrate for nicotinamide phosphoribosyltransferase (NAMPT)
NAMPTPhase 1Healthy AdultsDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06882096Nicotinamide Mononucleotide (NMN)Phase 1Healthy AdultsOtherDec 2026
NCT06882096Nicotinamide Mononucleotide (NMN)Phase 1Healthy AdultsOtherDec 2026
NCT06815991MIB-725Phase 1Healthy AdultsOtherDec 2026

Targets

NAMPT (1)

Companies with the same targets

ORIC Pharmaceuticals Remedy Plan

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.